Tag Archives: Rivaroxaban

Problems Continue Despite Gains In Oral Anticoagulant Use

Posted on by

Although significant progress has been made in recent years, a new survey from the European Society of Cardiology finds that there are still too many atrial fibrillation patients who are not taking...

FDA Panel Once Again Rejects New Indication For J&J Drug

Posted on by

The FDA’s Cardiovascular and Renal Drugs Advisory Committee once again turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s Xarelto...
    






Johnson & Johnson Faces Uphill Battle At FDA Advisory Panel

Posted on by

The third time may not be the charm. Twice before the FDA has turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s Xarelto (...